SALT LAKE CITY--(BUSINESS WIRE)--SignPath Pharma, Inc. reported in the March issue of Anticancer Research* that its proprietary intravenous liposomal curcumin (LipoCurc™) concentrates very intensely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback